Evolus (EOLS) 24th Annual Needham Virtual Healthcare Conference summary

Company overview and product portfolio

• Focuses on performance beauty with flagship neurotoxin Jeuveau and a cash-pay model.

• Achieved 14% market share in neurotoxin segment; launching Evolysse, a hyaluronic acid injectable gel, in Q2.

• Evolysse targets both volume restoration and dynamic wrinkles, with unique label language for weight loss-related facial changes.

• Co-branded media and consumer loyalty programs differentiate market approach.

Product differentiation and clinical data

• Evolysse uses a novel cold cross-linking process, preserving HA structure and reducing fragmentation.

• Demonstrated statistical superiority over Restylane Lidocaine in clinical trials, with longer duration and natural look.

• Suitable for dynamic facial areas and weight loss-induced wrinkles, with a clean safety profile.

• Training and adoption supported by clinician-led medical affairs team.

Market landscape and launch strategy

• Filler and toxin markets have similar competitive sets; Jeuveau holds 14% share in a $2.7B toxin market.

• Filler market is $1.8B in the US, less brand-dominated than toxins, with more flexibility for new entrants.

• Launch strategy prioritizes existing high-value accounts, with gradual expansion to new accounts.

• Uptake modeled conservatively compared to RHA filler launch; existing customer base of 15,000 accounts.